ARTICLE
2 June 2023

Alvotech And Advanz Pharma Extend Partnership To Commercialize Five Proposed Biosimilars In Europe

GP
Goodwin Procter LLP

Contributor

At Goodwin, we partner with our clients to practice law with integrity, ingenuity, agility, and ambition. Our 1,600 lawyers across the United States, Europe, and Asia excel at complex transactions, high-stakes litigation and world-class advisory services in the technology, life sciences, real estate, private equity, and financial industries. Our unique combination of deep experience serving both the innovators and investors in a rapidly changing, technology-driven economy sets us apart.
Advanz Pharma ("Advanz") and Alvotech announced that they entered an exclusive partnership agreement regarding supply and commercialization of five biosimilars in Europe, with Alvotech responsible for the development and commercial supply of the biosimilars, and Advanz responsible for registration and commercialization in Europe.
United States Food, Drugs, Healthcare, Life Sciences

Advanz Pharma ("Advanz") and Alvotech announced that they entered an exclusive partnership agreement regarding supply and commercialization of five biosimilars in Europe, with Alvotech responsible for the development and commercial supply of the biosimilars, and Advanz responsible for registration and commercialization in Europe. Per the announcement, the agreement includes proposed biosimilars to SIMPONI® (golimumab) and ENTYVIO® (vedolizumab) and three undisclosed, early stage biosimilar candidates. According to IQVIA, the current market for these five biosimilars covered by the agreement, within the markets covered by the agreement, exceeds $4 billion.

Furthermore, this recent agreement builds upon a previous collaboration between the two companies. In February, Advanz and Alvotech entered an agreement to commercialize AVT23, a proposed biosimilar to XOLAIR® (omalizumab). That agreement covered the European Economic Area, the United Kingdom, Switzerland, Canada, Australia, and New Zealand.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More